What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study

被引:207
|
作者
Leshem, Y. A. [1 ]
Hajar, T. [1 ]
Hanifin, J. M. [1 ]
Simpson, E. L. [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA
关键词
PERCEIVED AGE; ORTHODONTIC TREATMENT; PHOTONUMERIC SCALE; FACIAL APPEARANCE; LEIDEN LONGEVITY; SKIN; WOMEN; SMOKING; PHOTODAMAGE; MORTALITY;
D O I
10.1111/bjd.13662
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. Objectives To evaluate the interpretability and the ease of use of the EASI. Methods A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. Results The suggested severity strata for the EASI are as follows: 0 = clear; 0.1-1.0 = almost clear; 1.1-7.0 = mild; 7.1-21.0 = moderate; 21.1-50.0 = severe; 50.1-72.0 = very severe (kappa = 0.75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. Conclusions Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials.
引用
收藏
页码:1353 / 1357
页数:5
相关论文
共 50 条
  • [31] Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
    Ariens, Lieneke F. M.
    Gadkari, Abhijit
    van Os-Medendorp, Harmieke
    Ayyagari, Rajeev
    Terasawa, Emi
    Kuznik, Andreas
    Chen, Zhen
    Bego-Le Bagousse, Gaelle
    Lu, Yufang
    Rizova, Elena
    Graham, Neil M. H.
    Pirozzi, Gianluca
    De Bruin-Weller, Marjolein
    Eckert, Laurent
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (10) : 851 - 857
  • [32] What plays a role in the severity of atopic dermatitis in children?
    Cansever, Murat
    Oruc, Cigdem
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2021, 51 (05) : 2494 - 2501
  • [33] The Eczema Area and Severity Index-A Practical Guide
    Hanifin, Jon M.
    Baghoomian, Wenelia
    Grinich, Erin
    Leshem, Yael A.
    Jacobson, Michael
    Simpson, Eric Lawrence
    DERMATITIS, 2022, 33 (03) : 187 - 192
  • [34] Paediatric atopic dermatitis: correlation between Eczema Area Severity Index, quality of life and visual analogue scale severity scores reported by children and their parents, and in different age groups
    Sambi, Pavan
    Warburton, Katharine
    Montgomery, Rachel
    Thompson, Mia
    Majeethia, Parisha
    Clark, Sheila
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [35] QUANTIFICATION OF THE EXTENT AND THE SEVERITY OF ATOPIC-DERMATITIS - THE ADASI SCORE
    BAHMER, FA
    SCHAFER, J
    SCHUBERT, HJ
    ARCHIVES OF DERMATOLOGY, 1991, 127 (08) : 1239 - 1240
  • [36] The Atopic Dermatitis Antecubital Severity score: validity, reliability, and sensitivity to change in patients with atopic dermatitis
    Baek, Ji Hwoon
    Park, Chun Wook
    Choi, Kyung Min
    Yang, Yoon Seok
    Lee, Soo Yun
    Koh, Jae Sook
    Chung, Bo Young
    Kim, Hye One
    Park, Gyeong-Hun
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2015, 54 (12) : 1382 - 1389
  • [37] Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies
    Simpson, Eric L.
    Kircik, Leon
    Blauvelt, Andrew
    Kuligowski, Michael E.
    Venturanza, May E.
    Sun, Kang
    Eichenfield, Lawrence F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB157 - AB157
  • [38] Epidemiological study of pediatric atopic dermatitis severity
    Silverberg, J.
    Paller, A.
    EXPERIMENTAL DERMATOLOGY, 2016, 25 : 42 - 42
  • [39] Dupilumab improved all domains of Eczema Area and Severity Index (EASI) and 5-D pruritus scale in adults with atopic dermatitis in a phase 2 study
    Hamilton, J.
    Ren, H.
    Weinstein, S. P.
    Pirozzi, G.
    Graham, N.
    Radin, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 : S104 - S104
  • [40] Development of an Eczema Area and Severity Index lesional severity atlas for diverse skin types
    Silverberg, J. I.
    Horeczko, J.
    Alexis, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E171 - E172